Drug-eluting stents: Clinical perspectives on drug and design differences

Reviews in Cardiovascular Medicine

Volumn 6, Issue SUPPL. 1, 2005, Pages

  Rogers, Campbell D K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bifurcation lesions; Paclitaxel; Sirolimus; Stent design

Indexed keywords

ABT 578; EVEROLIMUS; PACLITAXEL; POLYMER; RAPAMYCIN;

ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL WALL; CORONARY ARTERY DISEASE; CORONARY STENT; DEVICE; DRUG CHOICE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG STRUCTURE; HEART MUSCLE ISCHEMIA; HUMAN; RESTENOSIS;

BLOOD VESSEL PROSTHESIS IMPLANTATION; CELL CYCLE; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ARTERIOSCLEROSIS; DRUG DESIGN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOCARDIAL INFARCTION; PACLITAXEL; PROSTHESIS DESIGN; STENTS;

EID: 13644271075     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Morice M-C, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
2. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries. A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-195.
3. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
4. Axel DI, Kunert W, Göggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997; 96:636-645.
5. Grube E, Silber S, Hauptmann KE, et al. TAXUS I. Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:38-42.
6. Stone GW, Ellis SG, Cox DA, et al. A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004; 350:221-231.
7. Rogers CDK. Optimal stent design for drug delivery. Rev Cardiovasc Med. 5(suppl 2):S9-S15.
8. Moses JW, Kipshidze N, Leon MB. Perspectives of drug-eluting stents: the next revolution. Am J Cardiovasc Drugs. 2002; 2:163-172.
9. Dobesh PP, Stacy ZA, Ansara AJ, Enders JM. Drug-eluting stents: a mechanical and pharmacologic approach to coronary artery disease. Pharmacotherapy. 2004;24:1554-1577.
10. Doggrell SA. Sirolimus- or paclitaxel-eluting stents to prevent coronary artery restenosis Expert Opin Pharmacother. 2004;5:2209-2220.
11. McKeage K, Murdoch D, Goa KL. The sirolimus-eluting stent: a review of its use in the treatment of coronary artery disease. Am J Cardiovasc Drugs. 2003;3:211-230.
12. Grube E, Sonoda S, Ikeno F, et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation. 2004;109: 2168-2171.
13. Buellesfeld L, Grube E. ABT-578-eluting stents. Herz. 2004;29:167-170.
14. Taxol Package Insert. Bristol-Myers Squibb Company. Princeton, NJ.
15. Farb A, Heller PF, Shroff S, et al. Pathological analysis of paclitaxel via a polymer-coated stent. Circulation, 2001;104:473-479.
16. Drachman DE, Edelman ER, Kamath KR, et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol. 2000;36:2325-2332.
17. Van der Giessen, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996;94:1690-1697.
18. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19: 267-274.
19. Rogers C, Edelman ER. Endovascular stent design dictates experimental restenosis and thrombosis. Circulation. 1995;91:2995-3001.
20. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting. Circulation. 1999;99:44-52.
21. Garasic JM, Edelman ER, Squire JC, et al. Stent and artery geometry determine intimal thickening independent of arterial injury. Circulation. 2000;101:812-818.
22. Hwang C-W, Wu D, Edelman ER. Physiological transport forces govern drug delivery distribution for stent-based delivery. Circulation. 2001; 104:600-605.
23. Sousa JE, Costa MA, Abizaid A, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis. A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2003;107:24-27.
24. Degertekin M, Serruys PW, Foley DP, et al. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation. Long-term (up to 2 years) clinical, angiographic and intravascular ultrasound follow-up. Circulation 2002; 106:1610-1613.
25. Liistro F, Stankovic G, Di Mario C, et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis. Immediate and long-term clinical and angiographic outcome. Circulation. 2002;105:1883-1886.
26. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based paclitaxel-eluting TAXUS stent. The TAXUS IV Trial. Circulation. 2004;109:1942-1947.
27. Birkenhauer P, Yang Z, Gander B. Preventing restenosis in early drug-eluting stent era: recent developments and future perspectives. J Pharm Pharmacol. 2004;56:1339-1356.
28. Serruys PW. SPIRIT FIRST: Initial Results With the Durable Polymer-Based Everolimus-Eluting Stent. Presented at Transcatheter Cardiovascular Therapeutics 2004. September 28, 2004. Washington, DC.
29. Dawkins KD. TAXUS VI. Presented at EuroPCR: The Paris Course on Revascularization; May 25-28, 2004; Paris, France.
30. Hoye A, Lemos PA, Tanabe K, et al. Low repeat revascularization rates following drug-eluting stent implantation in de novo bifurcation lesions. Presented at the American College of Cardiology 53rd Annual Scientific Session; March 7-10, 2004; New Orleans, LA.
31. Richter Y, Groothuis, Seifert P, et al. Dynamic flow alterations dictate leukocyte adhesion and response to endovascular interventions. J Clin Invest. 2004; 113:1607-1614.
32. Lemos PA, Saia F, Hofma SH, et al. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol. 2004;43:704-708.
33. Ong ATL, Lemos PA, Hoye A, et al. Safety and Feasibility of Paclitaxel-Eluting Stents in the Treatment of ST-Elevation Myocardial Infarction. Presented at the American College of Cardiology Annual Scientific Session. March 7-10, 2004. New Orleans, LA.